clinical trial · NCT06958536
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Crohn's DiseasebrivekimigPlacebo
brief summary
This is a phase 2, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
started
Jun 3, 2025
primary completion
Dec 17, 2026
completion
Oct 17, 2029
last updated
Nov 19, 2026
official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Brivekimig in Adults With Moderate to Severe Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol